Localized scleroderma (also called morphea) is a term encompassing a spectrum of
sclerotic autoimmune diseases that primarily affect the skin, but also might involve …

Objectives To assess the long‐term efficacy and tolerability of mycophenolate mofetil (MMF)
in patients with diffuse cutaneous systemic sclerosis (dc SS c). Methods Patients enrolled in …

BACKGROUND: In previous trials, UV therapy has been demonstrated to be effective in the
treatment of localized scleroderma (LS). To date, a randomized comparison study to …

Key points Patients with severe rapidly progressive systemic sclerosis (SSc) have a poor
prognosis. Standard immunosuppressive therapies may have modest effects on stabilizing …

SIR—E Dippel and colleagues (July 5, p 32–33) 1 showed that treatment with extracorporeal
photopheresis (ECP) and interferon-2a was associated with a higher response rate than …

Induction of apoptosis and changes to cytokine secretion patterns have been implicated in
the mechanism of action of extracorporeal photopheresis (ECP). Lymphocyte apoptosis is …

Seven patients, 4 women and 3 men afflicted with severe progressive systemic sclerosis
(PSS) were treated with Plasma Exchange after failure of different other treatment. All …

There are two major clinical subsets of scleroderma:(i) systemic sclerosis (SSc) is a complex
systemic autoimmune disorder characterized by inflammation, vasculopathy, and excessive …

Localized scleroderma is a chronic inflammatory disease primarily of the dermis and
subcutaneous fat that ultimately leads to a scar-like sclerosis of connective tissue. The …

In an uncontrolled clinical trial, plasmapheresis combined with prednisone and
cyclophosphamide therapy produced clinical improvement in 14 of 15 scleroderma patients …